Menu
Back to Journals » Breast Cancer: Targets and Therapy » Volume 13
Breast Cancer: Targets and Therapy
- View all (306)
- Volume 13, 2021 (13)
- Volume 12, 2020 (27)
- Volume 11, 2019 (32)
- Volume 10, 2018 (24)
- Volume 9, 2017 (64)
- Volume 8, 2016 (26)
- Volume 7, 2015 (36)
- Volume 6, 2014 (20)
- Volume 5, 2013 (13)
- Volume 4, 2012 (22)
- Volume 3, 2011 (16)
- Volume 2, 2010 (9)
- Volume 1, 2009 (4)
Archive: Volume 13, 2021
FOXQ1 is Differentially Expressed Across Breast Cancer Subtypes with Low Expression Associated with Poor Overall Survival
Elian FA, Are U, Ghosh S, Nuin P, Footz T, McMullen TPW, Brindley DN, Walter MA
Breast Cancer: Targets and Therapy 2021, 13:171-188
Published Date: 1 March 2021
An Update on the Molecular Pathology of Metaplastic Breast Cancer
McCart Reed AE, Kalaw EM, Lakhani SR
Breast Cancer: Targets and Therapy 2021, 13:161-170
Published Date: 26 February 2021
Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
Linehan AS, Fitzpatrick OM, Morris PG
Breast Cancer: Targets and Therapy 2021, 13:151-159
Published Date: 25 February 2021
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
Yuan P, Xu B
Breast Cancer: Targets and Therapy 2021, 13:135-150
Published Date: 24 February 2021
Breast Cancer Screening Practice and Associated Factors Among Women Aged 20–70 Years in Urban Settings of SNNPR, Ethiopia [Corrigendum]
Assefa AA, Abera G, Geta M
Breast Cancer: Targets and Therapy 2021, 13:133-134
Published Date: 22 February 2021
The Impact of AC and AC-T Chemotherapy’s Toxicities on Quality of Life Among Women with Breast Cancer in Ethiopia: A Prospective Patient-Reported Outcomes Study
Gadisa DA, Wang SH, Yimer G
Breast Cancer: Targets and Therapy 2021, 13:107-132
Published Date: 24 February 2021
In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach
Fleisher B, Lezeau J, Werkman C, Jacobs B, Ait-Oudhia S
Breast Cancer: Targets and Therapy 2021, 13:87-105
Published Date: 18 February 2021
Genetic Influences in Breast Cancer Drug Resistance
Daniyal A, Santoso I, Gunawan NHP, Barliana MI, Abdulah R
Breast Cancer: Targets and Therapy 2021, 13:59-85
Published Date: 9 February 2021
The Breast Tumor Microenvironment: Could Silicone Breast Implant Elicit Breast Carcinoma?
Fleury E, Nimir C, D'Alessandro GS
Breast Cancer: Targets and Therapy 2021, 13:45-58
Published Date: 15 January 2021
Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
da Silva JL, Rodrigues FR, de Mesquita GG, Fernandes PV, Thuler LCS, de Melo AC
Breast Cancer: Targets and Therapy 2021, 13:31-44
Published Date: 11 January 2021
Breast Cancer Screening Practices in a Tertiary Care Center in the State of Qatar: A Cross-Sectional Survey
Parambil JV, Najim M, Mahmoud M, Abubeker IY, Kartha A, Calaud F, Al-Mohamed A, Al-Mohannadi D, Chandra P, A Yassin M
Breast Cancer: Targets and Therapy 2021, 13:21-30
Published Date: 8 January 2021
Breast Cancer Screening Practice and Associated Factors Among Women Aged 20–70 Years in Urban Settings of SNNPR, Ethiopia
Assefa AA, Abera G, Geta M
Breast Cancer: Targets and Therapy 2021, 13:9-19
Published Date: 8 January 2021
MicroRNA-223 is Associated with Resistance Towards Platinum-based Chemotherapy and Worse Prognosis in Indonesian Triple-negative Breast Cancer Patients
Purwanto I, Heriyanto DS, Widodo I, Hakimi M, Hardianti MS, Aryandono T, Haryana SM
Breast Cancer: Targets and Therapy 2021, 13:1-7
Published Date: 6 January 2021